TCTMD -- Treating patients undergoing primary percutaneous coronary intervention (PCI) with bivalirudin rather than heparin and a glycoprotein IIb/IIIa inhibitor (GPI) reduces long-term mortality only in those at high risk, according to a subanalysis of the HORIZONS-AMI trial published in the August 2010 issue of JACC: Cardiovascular Interventions.
